May 31, 2023
Bayer Corp. is pushing back against a bid for attorney fees by the former legal team of a whistleblower who secured a more than $40 million settlement in suits in New Jersey and Minnesota alleging the company downplayed the risks of some of its drugs, saying their requests for millions in fees should be either substantially reduced or nixed altogether.
September 02, 2022
The U.S. Department of Justice on Friday announced that it had reached a $40 million settlement with Bayer AG to end allegations that the company violated the False Claims Act over three of its drugs, ending years of litigation in two whistleblower suits.
December 12, 2018
The federal government has weighed in on a whistleblower suit accusing Bayer Corp. of paying kickbacks to get doctors to use a surgery drug called Trasylol, saying the company can still be held liable under the False Claims Act even though the government pays for the drugs as part of a bundle rather than individually.
June 09, 2015
A New Jersey federal judge declined Monday to reconsider his order allowing two False Claims Act claims in a whistleblower's long-running suit against Bayer Corp. for allegedly pushing off-label uses of heart surgery drug Trasylol.
February 17, 2015
A New Jersey federal judge has agreed to review recent decisions supporting arguments that Bayer Pharmaceutical Corp. should repay the government for allegedly off-label marketed drugs in a whistleblower False Claims Act suit he largely dismissed last year due to ambiguity over whether the government can recoup the funds.
May 21, 2014
A New Jersey federal judge on Tuesday declined to reconsider the dismissal of much of a long-running employee whistleblower False Claims Act suit against Bayer Corp., saying the company is not required to repay the government for drugs it marketed off-label and those for which it received reimbursements.
April 14, 2014
A New Jersey federal judge on Friday cut down a long-running employee whistleblower suit accusing Bayer Corp. of fleecing government health programs by pushing off-label uses of heart-surgery drug Trasylol and breaching anti-kickback law, ruling that violations of federal misbranding law alone are insufficient to trigger False Claims Act liability.
September 03, 2013
A New Jersey federal judge on Friday narrowed a Bayer Corp. whistleblower's suit over alleged False Claims Act infractions tied to two drugs, tossing claims for violative off-label marketing but not for breaches of federal anti-kickback law.
August 22, 2012
A New Jersey federal judge on Tuesday separated a consolidated false claims whistleblower lawsuit over allegations Bayer AG wrongly promoted off-label uses for its heart surgery drug Trasylol, saying the two relators can't proceed together.